GPR35; PTAFR; FFAR1; FFAR4; HTR2C; DRD4; ADORA3; ADRA2C; ADRA2A; ADRA2B; DRD3; | |
GRM1; GRM5; GABBR1; GRM3; GRM8; GRM4; GRM2; | |
OPRD1; TSHR; NPSR1; CXCR1; NMUR2; | |
ALPL; RECQL; TDP1; PLA2G1B; BLM; ALPI; APOBEC3G; GLA; CTDSP1; P4HB; PKM; PIK3CG; TERT; PIK3R1; TK1; GLO1; HPGD; PGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; AKR1B10; NOX4; USP2; BRCA1; TNKS; PARP1; TNKS2; PYGL; PNP; APEX1; GDA; AOX1; CD38; POLB; | |
MGAM; ACHE; GAA; | |
PTPN1; | |
GRIK2; GRIA4; GRIK5; GRIK1; GRIK3; GRIA2; | |
GLRA2; GLRA1; | |
GABRR1; | |
CFTR; | |
P2RX1; | |
BCL2; | |
TOP2A; | |
AKT1; MET; CAMK2B; GSK3B; CDK8; NEK6; CSNK2A1; DAPK1; SYK; AXL; FLT3; PKN1; ABL1; SRC; IGF1R; PTK2; AURKB; DYRK1A; INSR; KDR; CDK1; MAPK1; MAPK14; EGFR; PIM1; NUAK1; ALK; MYLK; CDK9; NEK2; CDK6; | |
CA14; CA7; CA3; CA5A; CA1; CA12; CA4; CA6; CA2; CA9; CA5B; | |
AR; | |
THRB; | |
PPARD; PPARA; PPARG; | |
NR1I2; | |
ESRRB; ESRRA; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; PTGS1; PTGS2; ALOX5; TYR; XDH; | |
MMP13; MMP12; MMP3; MMP2; MMP14; MMP9; MMP1; | |
BACE1; | |
TLR2; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
KMT2A; | |
DNMT1; | |
EP300; | |
SLC6A1; SLC6A11; SLC22A8; SLC22A6; SLC1A1; SLCO1B3; SLCO1B1; | |
VCP; | |
ABCC1; ABCB1; ABCG2; | |
LMNA; FABP4; MCL1; MAPT; FABP3; SAE1; FABP5; THPO; HTT; RAB9A; NPC1; FABP2; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Bromodomain | EP300 | Histone acetyltransferase p300 | Q09472 | CHEMBL3784 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
Endoplasmic reticular retrotranslocon family | VCP | Transitional endoplasmic reticulum ATPase | P55072 | CHEMBL1075145 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | PNP | Purine nucleoside phosphorylase | P00491 | CHEMBL4338 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | GDA | Guanine deaminase | Q9Y2T3 | CHEMBL3129 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
Glycine receptor | GLRA2 | Glycine receptor subunit alpha-2 | P23416 | CHEMBL5871 |
Glycine receptor | GLRA1 | Glycine receptor subunit alpha-1 | P23415 | CHEMBL5845 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
Ionotropic glutamate receptor | GRIK2 | Glutamate receptor ionotropic kainate 2 | Q13002 | CHEMBL3683 |
Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP14 | Matrix metalloproteinase 14 | P50281 | CHEMBL3869 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
P2X receptor | P2RX1 | P2X purinoceptor 1 | P51575 | CHEMBL2094 |
Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | CDK9 | Cyclin-dependent kinase 9 | P50750 | CHEMBL3116 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | PTAFR | Platelet activating factor receptor | P25105 | CHEMBL250 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
Small molecule receptor (family C GPCR) | GRM5 | Metabotropic glutamate receptor 5 | P41594 | CHEMBL3227 |
Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
Small molecule receptor (family C GPCR) | GRM3 | Metabotropic glutamate receptor 3 | Q14832 | CHEMBL2888 |
Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
Small molecule receptor (family C GPCR) | GRM4 | Metabotropic glutamate receptor 4 | Q14833 | CHEMBL2736 |
Small molecule receptor (family C GPCR) | GRM2 | Metabotropic glutamate receptor 2 | Q14416 | CHEMBL5137 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | SAE1 | SUMO-activating enzyme subunit 1 | Q9UBE0 | CHEMBL1615388 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.476E-12 | 2.296E-10 | ABL1, AURKB, CA2, CA7, CFTR, DRD3, EGFR, HIF1A, HTT, MAPK1, MAPK14, NEK2, NPC1, NPSR1, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.676E-12 | 2.546E-10 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.032E-12 | 4.260E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, MPO, NOX4, PTGS1, PTGS2, SRC, TBXAS1 |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 3.311E-12 | 4.563E-10 | ADORA3, ADRA2A, ADRA2B, ADRA2C, ALK, AXL, CXCR1, DRD3, DRD4, EGFR, FFAR1, FFAR4, FLT3, GABBR1, GABRR1, GPR35, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HPGD, HTR2C, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, OPRD1, P2RX1, PPARG, PTAFR, TSHR |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.156E-11 | 1.439E-09 | ABCB1, ABCC1, ABCG2, ABL1, AKT1, ALK, AURKB, AXL, BLM, CAMK2B, CDK1, CDK6, CDK8, CDK9, CFTR, CSNK2A1, DAPK1, DYRK1A, EGFR, FLT3, GSK3B, IGF1R, INSR, KDR, MAPK1, MAPK14, MET, MYLK, NEK2, NEK6, NUAK1, P2RX1, PIK3CG, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TK1, TOP2A, TP53, VCP |
BP | GO:0023052; signaling | GO:0051966; regulation of synaptic transmission, glutamatergic | 1.451E-11 | 1.726E-09 | EGFR, GRIK1, GRIK2, GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, PTGS2 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.946E-11 | 2.230E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.769E-11 | 8.133E-09 | ALOX12, ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, TBXAS1, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.929E-10 | 1.908E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.777E-10 | 4.992E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.348E-10 | 7.046E-08 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.979E-09 | 1.545E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 2.163E-09 | 1.682E-07 | ADRA2B, ALK, CDK1, DRD4, GRM1, GRM4, INSR, MAPK1, MAPK14, PKN1, PLA2G1B, PTPN1, SYK |
BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 5.177E-09 | 3.745E-07 | APP, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 5.761E-09 | 4.154E-07 | AKT1, BCL2, CAMK2B, CDK1, CSNK2A1, DYRK1A, GSK3B, MAPK1, PKN1, TNKS |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 7.811E-09 | 5.452E-07 | AKT1, BCL2, HIF1A, LMNA, OPRD1, P4HB, PPARD, PTGS2, SRC, TERT, TP53 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 8.536E-09 | 5.864E-07 | AR, CDK1, CDK8, CDK9, ESR1, ESR2, ESRRA, ESRRB, NR1I2, PPARA, PPARD, PPARG, THRB |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.866E-09 | 6.651E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
CC | GO:0044456; synapse part | GO:0042734; presynaptic membrane | 1.107E-08 | 7.392E-07 | GABBR1, GRIK2, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.417E-08 | 9.238E-07 | ADRA2A, ADRA2B, ADRA2C, AKT1, AXL, MAPK1, P2RX1, PIK3CG, PIK3R1, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.015E-08 | 1.279E-06 | ABL1, EGFR, IGF1R, INSR, KDR, PTK2, SRC, SYK |
MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 2.312E-08 | 1.451E-06 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 2.910E-08 | 1.770E-06 | GLRA1, GLRA2, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, P2RX1 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.547E-08 | 2.612E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 4.894E-08 | 2.783E-06 | GRIK1, GRIK2, GRIK3, GRIK5 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.260E-08 | 3.982E-06 | CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
CC | GO:0044464; cell part | GO:0042995; cell projection | 1.233E-07 | 6.466E-06 | ABL1, ADRA2C, AKR1B1, APP, BACE1, CA2, CAMK2B, CDK6, DRD3, GABBR1, GLRA1, GLRA2, GRIA2, GRIA4, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM5, HIF1A, HTT, MAPK1, MAPT, MYLK, OPRD1, P2RX1, PKM, PTGS2, PTK2, SLC6A1, SLC6A11, SMN1, SMN2, SRC, TLR2 |
CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 2.256E-07 | 1.104E-05 | GABBR1, GABRR1, GLRA1, GLRA2, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM3, OPRD1, P2RX1 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.875E-07 | 1.795E-05 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 3.956E-07 | 1.825E-05 | ABL1, BCL2, BRCA1, EP300, MCL1, PIK3R1, POLB, TP53 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.071E-07 | 1.874E-05 | ABCC1, ADRA2A, CA2, CA4, CA9, EGFR, HPGD, SLC22A6, SLC22A8, SLCO1B1, SLCO1B3, TSHR |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 4.343E-07 | 1.991E-05 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, AOX1, APOBEC3G, BCL2, BLM, CAMK2B, FLT3, GLA, GRIK2, HPGD, KMT2A, MAPT, MCL1, NFKB1, PTGS2, PYGL, SLC22A6, TERT, TOP2A, TYR, XDH |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 5.445E-07 | 2.445E-05 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 6.292E-07 | 2.785E-05 | APP, CDK1, EGFR, MAPK1, MAPK14, PARP1, PIK3R1, PTGS2, TLR2 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 6.692E-07 | 2.920E-05 | ADRA2A, ADRA2B, ADRA2C, DRD4 |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 6.789E-07 | 2.956E-05 | ADRA2A, ADRA2C, AHR, AXL, BCL2, EGFR, HIF1A, MCL1, NFKB1, P4HB, PIK3R1, PPARD, PPARG, SAE1, TLR2, TOP2A, TP53, TTR, TYR |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 6.893E-07 | 2.996E-05 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 6.926E-07 | 3.004E-05 | ADRA2A, DRD3, DRD4, GABBR1, GRM2, GRM3 |
BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 8.395E-07 | 3.529E-05 | ADRA2C, AKT1, CD38, EGFR, PTAFR, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 9.976E-07 | 4.138E-05 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.011E-06 | 4.169E-05 | ADRA2A, ADRA2B, ADRA2C, AKT1, INSR, SRC |
BP | GO:0007610; behavior | GO:0007612; learning | 1.177E-06 | 4.807E-05 | APP, DRD3, GRM5, HIF1A, HTT, INSR, KMT2A, PTGS2, SLC6A1, TLR2 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.195E-06 | 4.837E-05 | EGFR, INSR, KDR, SYK |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.225E-06 | 4.951E-05 | HIF1A, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 1.331E-06 | 5.338E-05 | AHR, CDK9, ESR1, PPARA, TERT |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.336E-06 | 5.349E-05 | ABL1, BCL2, CA2, CA7, DRD3, HTR2C, HTT, KDR, NPSR1, PARP1, PLA2G1B, SRC |
MF | Unclassified; | GO:0032403; protein complex binding | 1.546E-06 | 6.111E-05 | ABL1, ACHE, ADRA2A, APEX1, EGFR, ESRRB, FLT3, IGF1R, INSR, KDR, MMP12, MMP13, MMP14, MMP9, P4HB, PIK3R1, PKM, PPARA, PTPN1, SRC, SYK, TLR2, TSHR, VCP |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.710E-06 | 6.723E-05 | AKT1, AURKB, BLM, BRCA1, CSNK2A1, DYRK1A, EP300, L3MBTL1, MAPK14, NUAK1, TP53 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 1.976E-06 | 7.643E-05 | ABCB1, ABCC1, ABCG2, NR1I2 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.434E-06 | 9.284E-05 | HIF1A, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 2.434E-06 | 9.284E-05 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.551E-06 | 9.696E-05 | ABL1, AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.231E-06 | 1.213E-04 | AXL, EGFR, INSR, MET, NOX4, PIK3CG, PIK3R1, PTK2, SRC, THPO |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 3.936E-06 | 1.445E-04 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.961E-06 | 1.445E-04 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.961E-06 | 1.445E-04 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 4.835E-06 | 1.737E-04 | ADRA2A, AKT1, FFAR1, GRIK5, HIF1A, INSR, NOX4, PIK3R1, PPARG, PYGL |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 4.881E-06 | 1.748E-04 | ABL1, AKT1, HIF1A, KDR, MAPK14, PTGS2 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 5.164E-06 | 1.843E-04 | AKT1, BCL2, HIF1A, MCL1, MMP9, PTGS2, PTPN1, SRC |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 6.260E-06 | 2.220E-04 | AR, BRCA1, CDK1, CFTR, EP300, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2, VCP |
MF | GO:0005488; binding | GO:0002039; p53 binding | 6.497E-06 | 2.293E-04 | BLM, EP300, GSK3B, HIF1A, HTT, NUAK1, TP53 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 6.547E-06 | 2.303E-04 | APP, GRM5, GSK3B, IGF1R, PARP1 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 7.905E-06 | 2.741E-04 | AKT1, BCL2, MAPT, PTPN1, TP53 |
BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 8.609E-06 | 2.966E-04 | BRCA1, CA2, EP300, ESR1, MAPK1, MMP14, PPARG |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 9.829E-06 | 3.334E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 1.045E-05 | 3.523E-04 | APEX1, APP, CFTR, NOX4, PIK3CG, PTAFR |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.126E-05 | 3.773E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3, PKM, PPARG |
MF | GO:0005488; binding | GO:0003682; chromatin binding | 1.295E-05 | 4.286E-04 | APEX1, AR, CDK1, CDK9, DNMT1, EGFR, EP300, ESR1, KMT2A, L3MBTL1, MPO, NFKB1, PKN1, PPARG, THRB, TOP2A, TP53 |
BP | GO:0050896; response to stimulus | GO:0031663; lipopolysaccharide-mediated signaling pathway | 1.334E-05 | 4.394E-04 | AKT1, MAPK1, MAPK14, PTAFR, TLR2 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.334E-05 | 4.394E-04 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.456E-05 | 4.753E-04 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.568E-05 | 5.073E-04 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 1.633E-05 | 5.262E-04 | BCL2, MCL1, PTK2, SRC |
MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 1.633E-05 | 5.262E-04 | CDK1, CDK8, CDK9, MAPK1 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.717E-05 | 5.507E-04 | AKR1B1, AKT1, AR, CFTR, EGFR, PPARG, SRC |
MF | GO:0005488; binding | GO:0001046; core promoter sequence-specific DNA binding | 1.747E-05 | 5.594E-04 | CDK9, EP300, ESR1, ESR2, KMT2A, PPARG, STAT6, TP53 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.951E-05 | 6.131E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 2.009E-05 | 6.286E-04 | ADRA2B, AR, DRD3, P2RX1, PPARA, PPARG, PTAFR, PTGS1, PTGS2 |
BP | GO:0032501; multicellular organismal process | GO:0051930; regulation of sensory perception of pain | 2.131E-05 | 6.583E-04 | ADRA2C, GRM1, NMUR2, OPRD1, PTAFR |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 2.131E-05 | 6.583E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 2.256E-05 | 6.908E-04 | CA3, CDK1, DRD3, GLRA1, GLRA2, HPGD, POLB, TP53 |
BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 3.061E-05 | 9.057E-04 | APP, CA2, CA7, DRD4, EGFR, GRIK2, MAPK1, PTGS2 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.140E-05 | 9.277E-04 | ABL1, ALOX15, APP, EGFR, FFAR4, HTR2C, KDR, NOX4, SRC, THPO |
MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 3.389E-05 | 9.814E-04 | AKT1, EGFR, ESR1 |
MF | GO:0005488; binding | GO:0070324; thyroid hormone binding | 3.389E-05 | 9.814E-04 | PKM, THRB, TTR |
MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 3.389E-05 | 9.814E-04 | ABCB1, ABCC1, ABCG2 |
CC | GO:0044421; extracellular region part | GO:0070062; extracellular exosome | 3.504E-05 | 1.009E-03 | ABCB1, ABCC1, AKR1B1, AKR1B10, ALDH1A1, ALK, ALOX12, ALPL, AOX1, APP, AXL, CA1, CA2, CA4, CA6, CD38, CDK1, CFTR, CTDSP1, FABP3, FABP4, FABP5, GAA, GDA, GLA, GLO1, GRM5, HPGD, INSR, MAPK1, MAPK14, MGAM, MMP9, MPO, MYLK, NPC1, P4HB, PGD, PKM, PNP, PTGS1, PYGL, RAB9A, SLC1A1, SLC22A6, SLC22A8, SRC, THRB, TTR, VCP |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 3.651E-05 | 1.047E-03 | CD38, CYP1A2, EGFR, ESR1, ESRRA, HPGD, PTGS2, SLC6A1 |
BP | GO:0008152; metabolic process | GO:0090407; organophosphate biosynthetic process | 4.110E-05 | 1.171E-03 | ACHE, ALOX15, ALPI, CSNK2A1, HTR2C, MAPK1, PIK3CG, PIK3R1, PKM, PLA2G1B, PNP, PPARD, PTAFR, PTGS2, PYGL, TK1 |
BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 4.389E-05 | 1.240E-03 | ACHE, CD38, GRIK2, GRIK3, PTGS2, SLC6A1 |
BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 4.822E-05 | 1.345E-03 | ADRA2A, AKT1, CDK1, DAPK1, ESRRB, GSK3B, HIF1A, HTT, INSR, KDR, PPARA, PTK2, PTPN1, VCP |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.164E-05 | 1.438E-03 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0009987; cellular process | GO:1903376; regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 5.383E-05 | 1.489E-03 | HIF1A, MCL1, PARP1 |
BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 5.383E-05 | 1.489E-03 | ADRA2A, ADRA2B, ADRA2C |
CC | GO:0044464; cell part | GO:0005829; cytosol | 5.582E-05 | 1.535E-03 | ABL1, AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AOX1, APOBEC3G, APP, AR, AURKB, BCL2, BLM, CA1, CA2, CA3, CA7, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, EP300, FABP2, FABP3, FABP4, FABP5, FLT3, GDA, GLO1, GSK3B, HIF1A, HPGD, HSD17B1, HTT, KMT2A, LMNA, MAPK1, MAPK14, MAPT, MCL1, MMP14, MYLK, NEK2, NEK6, NFKB1, PGD, PIK3CG, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PNP, PPARG, PTK2, PTPN1, PYGL, RAB9A, SMN1, SMN2, SRC, STAT6, SYK, TK1, TNKS, TNKS2, TP53, TYR, VCP, XDH |
MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 5.699E-05 | 1.561E-03 | APEX1, BLM, BRCA1, EP300, POLB, TP53 |
CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 5.699E-05 | 1.561E-03 | AKR1B1, GRIK2, GRIK3, HIF1A, MAPK1, MAPT |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 5.919E-05 | 1.617E-03 | DRD3, DRD4, PPARA, PPARG, TOP2A, TP53, USP2 |
CC | GO:0044464; cell part | GO:0030424; axon | 6.031E-05 | 1.646E-03 | ADRA2C, APP, BACE1, CA2, GRIK3, GRM2, GRM3, HTT, MAPK1, MAPT, SLC6A1 |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 6.105E-05 | 1.664E-03 | AKT1, AURKB, DYRK1A, MAPK1, MAPK14 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 6.263E-05 | 1.698E-03 | HPGD, MMP2, MMP9, TERT |
BP | GO:0065007; biological regulation | GO:0010952; positive regulation of peptidase activity | 6.786E-05 | 1.822E-03 | APP, DAPK1, MAPK14, MAPT, MMP14, P2RX1, PPARG, VCP, XDH |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 6.853E-05 | 1.831E-03 | AKT1, INSR, MAPK14, PIK3R1, TERT |
BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 7.522E-05 | 1.983E-03 | DRD3, DRD4, NMUR2, PLA2G1B |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 7.669E-05 | 2.014E-03 | AKR1B1, AKR1B10, ALDH1A1, AOX1, XDH |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 8.015E-05 | 2.093E-03 | APP, EGFR, MAPT |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 8.015E-05 | 2.093E-03 | BLM, RECQL, TP53 |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 8.486E-05 | 2.213E-03 | AKR1B1, APEX1, BCL2, BLM, GAA, HIF1A, KMT2A, NOX4, PARP1, SRC, TERT |
BP | GO:0032501; multicellular organismal process | GO:0032481; positive regulation of type I interferon production | 8.559E-05 | 2.224E-03 | EP300, MMP12, NFKB1, STAT6, SYK, TLR2 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 8.559E-05 | 2.224E-03 | AXL, KDR, MAPK14, PIK3R1, PTK2, SRC |
MF | GO:0005215; transporter activity | GO:0015347; sodium-independent organic anion transmembrane transporter activity | 8.955E-05 | 2.308E-03 | SLC22A6, SLC22A8, SLCO1B1, SLCO1B3 |
BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 1.004E-04 | 2.526E-03 | AOX1, XDH |
BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 1.004E-04 | 2.526E-03 | EGFR, NMUR2 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.004E-04 | 2.526E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.004E-04 | 2.526E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.004E-04 | 2.526E-03 | PTGS1, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.004E-04 | 2.526E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.004E-04 | 2.526E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0001641; group II metabotropic glutamate receptor activity | 1.004E-04 | 2.526E-03 | GRM2, GRM3 |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 1.052E-04 | 2.639E-03 | ADRA2A, BCL2, CD38, HTR2C, PARP1, SRC, TNKS, TNKS2 |
MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 1.052E-04 | 2.639E-03 | ABCB1, ABCC1, ABCG2, FABP3, HTT, NPC1, SLCO1B1, SLCO1B3 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.058E-04 | 2.641E-03 | FABP2, FABP3, FABP4, FABP5 |
CC | GO:0043226; organelle | GO:0016604; nuclear body | 1.103E-04 | 2.735E-03 | ABL1, AOX1, APEX1, AR, BLM, CDK9, DYRK1A, HIF1A, LMNA, MAPK14, MAPT, NEK6, NR1I2, SMN1, SMN2, TERT, THRB, TNKS, TP53 |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 1.136E-04 | 2.806E-03 | PPARG, SRC, TP53 |
BP | GO:0050896; response to stimulus | GO:0009410; response to xenobiotic stimulus | 1.158E-04 | 2.850E-03 | AHR, DRD3, DRD4, EGFR, PPARG, PTAFR, SLC6A1, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.445E-04 | 3.445E-03 | BRCA1, CYP1B1, HIF1A, PTGS2 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.445E-04 | 3.445E-03 | PARP1, SRC, TNKS, TNKS2 |
MF | GO:0005215; transporter activity | GO:0008381; mechanosensitive ion channel activity | 1.442E-04 | 3.445E-03 | CFTR, GABRR1, GLRA1, GLRA2, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, NMUR2, P2RX1 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.551E-04 | 3.655E-03 | AR, CYP19A1, ESR1 |
BP | GO:0008152; metabolic process | GO:0019371; cyclooxygenase pathway | 1.551E-04 | 3.655E-03 | PTGS1, PTGS2, TBXAS1 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 1.551E-04 | 3.655E-03 | IGF1R, INSR, PIK3R1 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 1.551E-04 | 3.655E-03 | GSK3B, HTT, MAPT |
CC | Unclassified; | GO:0106003; amyloid-beta complex | 1.551E-04 | 3.655E-03 | GRIA2, INSR, TLR2 |
MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 1.567E-04 | 3.676E-03 | ABL1, DYRK1A, PTK2, SRC, SYK |
BP | GO:0050896; response to stimulus | GO:0009612; response to mechanical stimulus | 1.617E-04 | 3.774E-03 | AKT1, EGFR, MAPK14, MMP14, MPO, NFKB1, PPARG, PTGS2, SRC |
MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 1.624E-04 | 3.783E-03 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.624E-04 | 3.783E-03 | GLRA1, GRIK2, GRIK3, GRIK5, MAPK1, SMN1, SMN2 |
BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 1.672E-04 | 3.874E-03 | AKT1, FABP3, PPARA, PPARG |
BP | GO:0051179; localization | GO:0043252; sodium-independent organic anion transport | 1.672E-04 | 3.874E-03 | SLC22A6, SLC22A8, SLCO1B1, SLCO1B3 |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 1.675E-04 | 3.876E-03 | ABL1, ALOX12, BRCA1, CYP1B1, HIF1A, KDR, PTGS2, TERT |
BP | GO:0002376; immune system process | GO:0045637; regulation of myeloid cell differentiation | 1.683E-04 | 3.890E-03 | CA2, CDK6, EP300, ESRRA, HIF1A, KMT2A, L3MBTL1, MAPK14, PIK3R1, THPO |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 1.714E-04 | 3.958E-03 | AHR, AR, EP300, ESR1, GSK3B, PPARA, TP53 |
MF | GO:0005488; binding | GO:0042165; neurotransmitter binding | 1.720E-04 | 3.967E-03 | ACHE, GLRA1, GLRA2, HTR2C, SLC6A11 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.925E-04 | 4.388E-03 | AXL, IGF1R, INSR, PIK3R1 |
BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 2.053E-04 | 4.622E-03 | ESR1, MAPK1, STAT6 |
BP | GO:0022610; biological adhesion | GO:0051893; regulation of focal adhesion assembly | 2.059E-04 | 4.622E-03 | ABL1, KDR, MMP14, PTK2, SRC |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 2.059E-04 | 4.622E-03 | BCL2, NOX4, PARP1, POLB, TP53 |
MF | GO:0005488; binding | GO:0043621; protein self-association | 2.059E-04 | 4.622E-03 | ACHE, DYRK1A, FLT3, PPARG, TP53 |
BP | GO:0065007; biological regulation | GO:0032092; positive regulation of protein binding | 2.151E-04 | 4.799E-03 | ABL1, APP, EP300, GSK3B, MMP9, TERT |
BP | GO:0007610; behavior | GO:0001662; behavioral fear response | 2.203E-04 | 4.886E-03 | BCL2, DRD4, GRIK2, HTR2C |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.227E-04 | 4.922E-03 | BCL2, CAMK2B, CDK1, CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, EGFR, GRIA2, HSD17B2, NOX4, PTGS1, PTGS2, RAB9A, TBXAS1, VCP |
BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 2.247E-04 | 4.942E-03 | AHR, DRD3, KMT2A, PPARA, USP2 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 2.247E-04 | 4.942E-03 | CDK1, EGFR, IGF1R, INSR, PLA2G1B |
BP | GO:0009987; cellular process | GO:0051260; protein homooligomerization | 2.420E-04 | 5.269E-03 | BLM, GLRA1, HSD17B10, P2RX1, PKM, SLC1A1, SLC22A6, SLC6A1, TK1, TP53, VCP |
MF | GO:0005488; binding | GO:0030332; cyclin binding | 2.510E-04 | 5.417E-03 | CDK1, CDK6, CDK9, USP2 |
BP | GO:0050896; response to stimulus | GO:0060359; response to ammonium ion | 2.600E-04 | 5.605E-03 | ABL1, DRD3, DRD4, MAPK1, PTAFR, SLC6A1 |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.649E-04 | 5.683E-03 | CYP19A1, HSD17B1, HSD17B2 |
CC | Unclassified; | GO:0043234; protein complex | 2.716E-04 | 5.802E-03 | ABL1, AHR, AKT1, ALK, APEX1, APOBEC3G, AR, AURKB, BCL2, BRCA1, CDK1, CDK6, CDK8, CDK9, CFTR, CSNK2A1, EGFR, EP300, ESR1, ESRRB, FLT3, GRIA2, GSK3B, HIF1A, HTT, IGF1R, INSR, MAPK1, MAPT, MCL1, NEK2, NEK6, NFKB1, P2RX1, P4HB, PARP1, PIK3R1, PKN1, POLB, PPARG, PTGS2, SLC22A6, SMN1, SMN2, SRC, SYK, TLR2, TNKS, TOP2A, TP53, TTR, VCP |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 2.735E-04 | 5.823E-03 | ADORA3, APP, AR, BCL2, CDK6, CYP1B1, FABP3, KMT2A, LMNA, NOX4, PKN1, PPARD, PPARG, PTGS2, TERT, TLR2, TP53, XDH |
BP | Unclassified; | GO:0099566; regulation of postsynaptic cytosolic calcium ion concentration | 2.991E-04 | 6.196E-03 | GRM1, GRM5 |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 2.991E-04 | 6.196E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.991E-04 | 6.196E-03 | CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 2.991E-04 | 6.196E-03 | GAA, MGAM |
BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 2.991E-04 | 6.196E-03 | ABL1, HIF1A |
BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 2.991E-04 | 6.196E-03 | ABCB1, ABCC1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.991E-04 | 6.196E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.991E-04 | 6.196E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.991E-04 | 6.196E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.991E-04 | 6.196E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 2.991E-04 | 6.196E-03 | GAA, MGAM |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.991E-04 | 6.196E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0099583; neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration | 2.991E-04 | 6.196E-03 | GRM1, GRM5 |
CC | GO:0032991; macromolecular complex | GO:0032983; kainate selective glutamate receptor complex | 2.991E-04 | 6.196E-03 | GRIK2, GRIK5 |
CC | GO:0044464; cell part | GO:0035578; azurophil granule lumen | 3.119E-04 | 6.450E-03 | FABP5, GLA, MAPK1, MPO, TTR, VCP |
BP | GO:0009987; cellular process | GO:0010822; positive regulation of mitochondrion organization | 3.154E-04 | 6.504E-03 | BCL2, GSK3B, HIF1A, HTT, KDR, MMP9, SAE1, TP53 |
BP | GO:0032501; multicellular organismal process | GO:1903708; positive regulation of hemopoiesis | 3.282E-04 | 6.748E-03 | AXL, CA2, HIF1A, MAPK14, MMP14, PNP, SYK, THPO |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 3.347E-04 | 6.842E-03 | CYP19A1, ESR1, SRC |
BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 3.614E-04 | 7.319E-03 | AKT1, BCL2, MCL1, TERT |
BP | GO:0050896; response to stimulus | GO:0071230; cellular response to amino acid stimulus | 3.660E-04 | 7.386E-03 | DNMT1, EGFR, GLRA1, GLRA2, MMP2 |
BP | GO:0051179; localization | GO:0030100; regulation of endocytosis | 3.821E-04 | 7.661E-03 | ABL1, ALOX15, APP, AXL, PPARG, PTPN1, SRC, SYK, TLR2 |
MF | GO:0005488; binding | GO:0001784; phosphotyrosine residue binding | 4.048E-04 | 8.057E-03 | ABL1, MAPK1, PIK3R1, SYK |
MF | GO:0003824; catalytic activity | GO:0004693; cyclin-dependent protein serine/threonine kinase activity | 4.048E-04 | 8.057E-03 | CDK1, CDK6, CDK8, CDK9 |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 4.152E-04 | 8.220E-03 | TERT, TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 4.152E-04 | 8.220E-03 | CA2, EGFR, SYK |
BP | Unclassified; | GO:0051571; positive regulation of histone H3-K4 methylation | 4.152E-04 | 8.220E-03 | BRCA1, DNMT1, KMT2A |
BP | GO:0032501; multicellular organismal process | GO:0045685; regulation of glial cell differentiation | 4.255E-04 | 8.407E-03 | APP, CDK1, DRD3, PPARG, TLR2 |
BP | GO:0009987; cellular process | GO:0014066; regulation of phosphatidylinositol 3-kinase signaling | 4.400E-04 | 8.655E-03 | EGFR, FLT3, KDR, MAPK1, PPARD, PTK2 |
BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 4.519E-04 | 8.848E-03 | BCL2, NOX4, SRC, TERT |
BP | GO:0065007; biological regulation | GO:1900274; regulation of phospholipase C activity | 4.519E-04 | 8.848E-03 | ABL1, EGFR, ESR1, PTAFR |
BP | GO:0009987; cellular process | GO:2001020; regulation of response to DNA damage stimulus | 4.633E-04 | 9.048E-03 | ABL1, BRCA1, CDK9, DYRK1A, EGFR, MAPT, MCL1, PARP1 |
CC | GO:0044464; cell part | GO:0005764; lysosome | 4.677E-04 | 9.109E-03 | AKR1B1, AKR1B10, GAA, GLA, MPO, NPC1, PIK3CG, RAB9A, SRC, TYR |
BP | GO:0008152; metabolic process | GO:0033138; positive regulation of peptidyl-serine phosphorylation | 4.908E-04 | 9.539E-03 | AKT1, APP, BCL2, EGFR, OPRD1, PTGS2 |
BP | GO:0051179; localization | GO:0051926; negative regulation of calcium ion transport | 4.920E-04 | 9.539E-03 | ADRA2A, BCL2, DRD4, GPR35, PTGS2 |
BP | GO:0008152; metabolic process | GO:0006081; cellular aldehyde metabolic process | 4.920E-04 | 9.539E-03 | AKR1B10, ALDH1A1, CYP1B1, GLO1, PGD |
BP | GO:0032501; multicellular organismal process | GO:0030540; female genitalia development | 5.073E-04 | 9.741E-03 | AXL, CYP19A1, ESR1 |
BP | GO:0050896; response to stimulus | GO:0070920; regulation of production of small RNA involved in gene silencing by RNA | 5.073E-04 | 9.741E-03 | EGFR, ESR1, TERT |
BP | GO:0032501; multicellular organismal process | GO:0048546; digestive tract morphogenesis | 5.073E-04 | 9.741E-03 | BCL2, EGFR, HIF1A |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.061E-20 | 1.952E-17 | ALPI, APOBEC3G, AR, BLM, BRCA1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DNMT1, EP300, ESR1, ESR2, ESRRA, ESRRB, GDA, GLO1, GLRA1, KMT2A, L3MBTL1, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, NR1I2, P2RX1, PARP1, PPARA, PPARD, PPARG, PTPN1, THRB, TK1, TNKS, TP53 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.039E-19 | 7.800E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | Unclassified; | GO:0004872; receptor activity | 4.570E-17 | 1.746E-14 | ADORA3, ADRA2A, ADRA2B, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD3, DRD4, EGFR, ESR1, ESR2, ESRRA, ESRRB, FFAR1, FFAR4, FLT3, GABBR1, GABRR1, GLRA1, GLRA2, GPR35, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HPGD, HTR2C, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, NR1I2, OPRD1, P2RX1, PPARA, PPARD, PPARG, PTAFR, THRB, TLR2, TSHR |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.191E-14 | 2.620E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.133E-13 | 5.686E-11 | ABL1, ADRA2A, AURKB, BCL2, CA2, CA7, CD38, CDK6, CFTR, DRD3, EGFR, HIF1A, HTR2C, HTT, KDR, MAPK1, MAPK14, NEK2, NPC1, NPSR1, PARP1, PLA2G1B, PTGS2, SRC, SYK, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 3.274E-13 | 5.891E-11 | GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 7.384E-23 | 1.580E-20 | OPRD1; GRIA2; THRB; GRIK5; PTAFR; GRIK3; HTR2C; GRIK1; GRIK2; GRM1; GRM3; GLRA1; GRM2; GABRR1; GLRA2; GRM5; GRM4; ADORA3; GRM8; DRD3; DRD4; GRIA4; GABBR1; GPR35; ADRA2C; ADRA2B; ADRA2A; TSHR; P2RX1; NMUR2 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.229E-13 | 8.769E-12 | GSK3B; FLT3; PIK3R1; PTGS2; HIF1A; EGFR; PIK3CG; IGF1R; ABL1; AKT1; EP300; MAPK1; MMP1; DAPK1; MMP2; MMP9; NFKB1; PTK2; AR; CDK6; BCL2; PPARG; MET; TP53; PPARD |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.323E-19 | 6.765E-17 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.345E-12 | 7.195E-11 | CAMK2B; SRC; MMP2; PIK3R1; MAPK14; HIF1A; ESR1; MMP9; PTK2; EGFR; PIK3CG; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 5.451E-12 | 2.333E-10 | GRIA2; GRIK5; SLC1A1; GRIK3; GRIK1; GRIK2; GRM1; GRM3; GRM2; GRM5; GRM4; GRM8; MAPK1; GRIA4 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.098E-11 | 2.017E-09 | GSK3B; AR; BCL2; AKT1; EP300; MAPK1; PIK3R1; TP53; EGFR; NFKB1; PIK3CG; IGF1R |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.430E-10 | 3.400E-09 | GSK3B; SYK; INSR; PIK3R1; BRCA1; PTK2; EGFR; NFKB1; PIK3CG; IGF1R; CDK6; KDR; BCL2; AKT1; MAPK1; PKN1; TP53; MET; TLR2; MCL1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.596E-11 | 2.017E-09 | APP; MAOA; ALOX15; HTR2C; ALOX12; CYP2C19; PTGS2; PTGS1; CYP2C9; CYP2C8; CYP2D6; ALOX5; MAPK1 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.332E-10 | 3.400E-09 | SYK; INSR; PIK3R1; EGFR; PIK3CG; GRM1; GRM3; GRM2; GRM5; GRM4; CXCR1; GRM8; AKT1; MAPK1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.182E-10 | 4.670E-09 | GABBR1; SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; EGFR; ESR2; PIK3CG; GRM1 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.491E-10 | 6.791E-09 | CAMK2B; INSR; BCL2; AKT1; EP300; MAPK1; PIK3R1; HIF1A; EGFR; NFKB1; PIK3CG; IGF1R |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 7.387E-10 | 1.216E-08 | DNMT1; ABCC1; ABCB1; BRCA1; PTGS2; MMP9; EGFR; NFKB1; CDK6; PIM1; ABL1; BCL2; CYP1B1; EP300; MAPK1; TP53; MET; MCL1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.056E-10 | 7.233E-09 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; TBXAS1; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.790E-09 | 3.317E-08 | DNMT1; GDA; PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; PNP; HSD17B1; ALOX5; HSD17B2; CD38; AOX1; TK1; XDH; MGAM; GAA; PGD; TYR; CYP2C9; CYP2C8; PKM; AKR1B10; TBXAS1; CYP1A2; ALDH1A1; CYP1A1; ALPL; ALPI |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.848E-09 | 2.341E-08 | SRC; PIK3R1; MMP9; NFKB1; PIK3CG; CDK6; BCL2; AKT1; EP300; MAPK1; STAT6; TP53; TLR2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.971E-10 | 1.371E-08 | PKM; FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; EGFR; PIK3CG |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.860E-09 | 2.341E-08 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; MAPK14; ESR1; NFKB1; ESR2; PIK3CG |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.122E-09 | 1.601E-08 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 7.085E-09 | 7.581E-08 | SRC; KDR; AKT1; MAPK1; PIK3R1; MAPK14; PTGS2; PTK2; PIK3CG |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.263E-08 | 1.175E-07 | CAMK2B; CDK6; AKT1; MAPK1; PIK3R1; TP53; EGFR; PIK3CG; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.224E-08 | 1.175E-07 | CAMK2B; GSK3B; SRC; ABL1; AKT1; MAPK1; PIK3R1; EGFR; PTK2; PIK3CG |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.088E-08 | 1.862E-07 | GSK3B; THRB; SRC; AKT1; EP300; MAPK1; PIK3R1; TP53; ESR1; HIF1A; PIK3CG |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.491E-08 | 1.974E-07 | CAMK2B; GSK3B; ABL1; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; TP53; NFKB1; PIK3CG |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.346E-08 | 1.974E-07 | HPGD; KMT2A; FLT3; MMP3; MPO; MMP9; NFKB1; PTK2; IGF1R; CDK9; PPARG; TP53; MET |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.962E-08 | 2.185E-07 | SYK; SRC; P2RX1; TBXAS1; AKT1; MAPK1; PIK3R1; MAPK14; PIK3CG; MYLK; PTGS1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.491E-08 | 1.974E-07 | OPRD1; ABCC1; ADORA3; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; TP53; NFKB1; PIK3CG |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.927E-09 | 5.550E-08 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53; EGFR |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.799E-08 | 2.139E-07 | CDK6; AKT1; MAPK1; PIK3R1; TP53; MET; EGFR; PIK3CG; IGF1R |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.691E-08 | 4.841E-07 | CAMK2B; GRIA2; GABBR1; PIK3R1; NFKB1; TSHR; PIK3CG; AKT1; EP300; MAPK1; PPARA; CFTR; GRIA4 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 9.165E-08 | 5.448E-07 | GSK3B; SYK; CSNK2A1; PIK3R1; MAPK14; NFKB1; PIK3CG; BCL2; CDK1; AKT1; CD38; EP300; TP53 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 9.165E-08 | 5.448E-07 | GSK3B; SRC; PIK3R1; PTK2; EGFR; PIK3CG; MYLK; IGF1R; KDR; BCL2; AKT1; MAPK1; MET |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.051E-08 | 2.890E-07 | PTPN1; CSNK2A1; SRC; INSR; EP300; MAPK1; MET; EGFR; IGF1R |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.183E-07 | 6.842E-07 | MMP14; MMP3; AKT1; MAPK1; PIK3R1; MAPK14; PTGS2; MMP9; NFKB1; PIK3CG |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.469E-08 | 4.326E-07 | ALK; CDK6; AKT1; MAPK1; PIK3R1; TP53; EGFR; PIK3CG |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 6.469E-08 | 4.326E-07 | FABP4; INSR; AKT1; PIK3R1; PTGS2; TSHR; PIK3CG; PTGS1 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 6.113E-07 | 2.973E-06 | MMP2; PIM1; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.463E-08 | 4.840E-07 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG; PPARD |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.525E-07 | 8.589E-07 | CDK6; BCL2; AKT1; PIK3R1; PTGS2; TP53; NFKB1; PTK2; PIK3CG |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.002E-07 | 3.495E-06 | POLB; CDK6; PKM; SYK; SRC; CDK1; EP300; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 7.289E-07 | 3.250E-06 | OPRD1; ADORA3; INSR; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2B; ADRA2A; PIK3CG; MYLK |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 7.020E-07 | 3.197E-06 | INSR; AKT1; EP300; MAPK1; PIK3R1; MAPK14; EGFR; PIK3CG; GRM1; IGF1R |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 7.020E-07 | 3.197E-06 | GSK3B; AKT1; MAPK1; PIK3R1; MAPK14; PPARA; TP53; EGFR; NFKB1; PIK3CG |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.126E-06 | 4.723E-06 | PARP1; LMNA; BCL2; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG; MCL1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.408E-07 | 1.321E-06 | CDK6; AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1; PIK3CG |
hsa05162 | Measles_Homo sapiens_hsa05162 | 8.624E-07 | 3.691E-06 | GSK3B; CDK6; CSNK2A1; AKT1; RAB9A; PIK3R1; TP53; NFKB1; PIK3CG; TLR2 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.319E-07 | 2.647E-06 | CDK6; ABL1; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.445E-09 | 9.625E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.334E-06 | 8.762E-06 | PLA2G1B; INSR; KDR; ABL1; AKT1; MAPK1; PIK3R1; MET; EGFR; NFKB1; PIK3CG; IGF1R |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.167E-06 | 4.805E-06 | PTPN1; GSK3B; INSR; AKT1; PIK3R1; PYGL; PPARA; NFKB1; PIK3CG |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.420E-07 | 1.785E-06 | CYP2C9; CYP2C8; MAOA; CYP2D6; CYP1A2; AOX1; CYP3A4; CYP2C19 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.420E-07 | 1.785E-06 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.372E-06 | 1.223E-05 | THPO; PIM1; BCL2; AKT1; AOX1; EP300; STAT6; PIK3R1; PIK3CG; MCL1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.280E-07 | 2.181E-06 | SLCO1B1; ABCB1; CA2; SLCO1B3; SLC22A8; CYP3A4; CFTR; ABCG2 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.272E-06 | 8.681E-06 | ALOX5; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG; TLR2 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 7.087E-06 | 2.333E-05 | SRC; INSR; KDR; AKT1; MAPK1; PIK3R1; MAPK14; MET; EGFR; PIK3CG; IGF1R |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 4.751E-06 | 1.640E-05 | CAMK2B; GRIA2; GSK3B; MAOA; AKT1; MAPK14; DRD3; DRD4; GRIA4 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 9.713E-06 | 3.102E-05 | CAMK2B; SYK; SRC; BCL2; AKT1; EP300; MAPK1; MAPK14; NFKB1; TLR2 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.703E-06 | 1.299E-05 | INSR; AKT1; PPARG; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.443E-05 | 7.577E-05 | CAMK2B; SRC; CD38; MAPK1; PIK3R1; PTGS2; EGFR; PIK3CG; MYLK |
hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 6.345E-06 | 2.155E-05 | GRIA2; GABRR1; GRM5; MAPK1; MAPK14; PTGS2; GRM1; GRIA4 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.309E-06 | 5.286E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 6.706E-07 | 3.189E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; EGFR; PIK3CG |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.478E-05 | 1.313E-04 | SYK; AKT1; MAPK1; PPARG; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 6.772E-05 | 1.834E-04 | CAMK2B; GRM5; P2RX1; PTAFR; HTR2C; CD38; EGFR; GRM1; MYLK |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.950E-05 | 9.019E-05 | CAMK2B; MMP14; SRC; MMP2; MAPK1; MAPK14; EGFR |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 6.462E-05 | 1.773E-04 | PTPN1; GSK3B; INSR; AKT1; MAPK1; PIK3R1; PYGL; PIK3CG |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 4.763E-05 | 1.359E-04 | CAMK2B; SRC; HTR2C; ALOX12; PIK3R1; MAPK14; PIK3CG |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 4.763E-05 | 1.359E-04 | CDK1; AKT1; MAPK1; PIK3R1; MAPK14; PIK3CG; IGF1R |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 6.878E-06 | 2.300E-05 | GSK3B; SYK; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.271E-06 | 8.681E-06 | GSK3B; BCL2; AKT1; MAPK1; PIK3R1; TP53; PIK3CG |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 7.512E-05 | 1.960E-04 | GSK3B; ESRRB; AKT1; MAPK1; PIK3R1; MAPK14; PIK3CG; IGF1R |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.371E-05 | 7.462E-05 | GRM5; SRC; CDK1; HTR2C; MAPK1; EGFR; GRM1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 9.078E-05 | 2.286E-04 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2; PIK3CG |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.481E-06 | 1.242E-05 | AKT1; EP300; MAPK1; PIK3R1; MET; HIF1A; PIK3CG |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 6.965E-05 | 1.840E-04 | GSK3B; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.167E-04 | 7.368E-04 | GSK3B; AKT1; EP300; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.137E-06 | 1.158E-05 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 6.965E-05 | 1.840E-04 | AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG; TLR2 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 7.861E-05 | 2.003E-04 | AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG; TLR2 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.052E-04 | 2.587E-04 | CAMK2B; ACHE; BCL2; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 2.098E-04 | 5.044E-04 | INSR; AKT1; PPARG; PIK3R1; CFTR; PIK3CG; IGF1R |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 6.904E-04 | 1.492E-03 | GSK3B; INSR; AKT1; PIK3R1; PPARA; NFKB1; PIK3CG |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 6.129E-04 | 1.338E-03 | CAMK2B; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; PIK3CG |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 9.655E-04 | 1.978E-03 | POLB; GSK3B; TERT; AKT1; EP300; PIK3R1; TP53; NFKB1; PIK3CG |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.435E-06 | 5.686E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 4.975E-03 | 8.872E-03 | SRC; MAPK1; PIK3R1; PTK2; EGFR; PIK3CG; MYLK |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.652E-03 | 5.112E-03 | CAMK2B; GSK3B; CSNK2A1; EP300; TP53; PPARD |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.552E-04 | 1.015E-03 | AKT1; MAPK1; PIK3R1; HIF1A; EGFR; PIK3CG |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.242E-02 | 2.045E-02 | AKT1; MAPK1; MAPT; MAPK14; TP53; EGFR; NFKB1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 9.467E-03 | 1.595E-02 | CSNK2A1; CDK1; EP300; TP53; NFKB1; TLR2 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 4.552E-04 | 1.015E-03 | CAMK2B; PKM; AKT1; EP300; PYGL; PPARA |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 5.120E-05 | 1.423E-04 | SYK; AKT1; MAPK1; PIK3R1; MAPK14; PIK3CG |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 6.020E-03 | 1.056E-02 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.335E-03 | 2.671E-03 | GSK3B; CDK6; ABL1; CDK1; EP300; TP53 |
hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 4.319E-05 | 1.284E-04 | CAMK2B; GRIA2; GRM5; EP300; MAPK1; GRM1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.919E-04 | 6.863E-04 | SYK; CSNK2A1; PARP1; BCL2; PTGS2; NFKB1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.034E-03 | 2.087E-03 | MMP2; PIK3R1; MAPK14; MMP9; PTK2; PIK3CG |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 7.008E-03 | 1.210E-02 | CAMK2B; AR; CDK1; MAPK1; IGF1R |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 7.996E-03 | 1.358E-02 | GSK3B; ABL1; MAPK1; MET; PTK2 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.917E-03 | 5.382E-03 | CAMK2B; GSK3B; EP300; MAPK1; TYR |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.126E-03 | 4.137E-03 | SYK; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.917E-03 | 5.382E-03 | PIK3R1; NFKB1; PTK2; PIK3CG; TLR2 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.427E-02 | 2.313E-02 | CA2; PLA2G1B; CD38; CFTR |
hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 1.377E-02 | 2.250E-02 | CAMK2B; GRIA2; MAPK1; GRIA4 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.120E-05 | 1.423E-04 | CXCR1; SRC; MAPK14; MET; EGFR; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.650E-05 | 1.972E-04 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 1.666E-03 | 3.272E-03 | GABBR1; GABRR1; SRC; SLC6A11; SLC6A1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 9.824E-03 | 1.642E-02 | MAPK1; PKN1; MAPK14; NFKB1 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 3.061E-02 | 4.647E-02 | AKT1; PPARA; NFKB1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 9.707E-04 | 1.978E-03 | SRC; PIK3R1; MET; PTK2; PIK3CG |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.181E-04 | 1.537E-03 | MAPK1; MAPK14; PTGS2; NFKB1; TLR2 |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 2.951E-02 | 4.510E-02 | CDK6; CDK1; TP53 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 5.821E-03 | 1.030E-02 | CAMK2B; CA2; CFTR; MYLK |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 3.910E-04 | 8.998E-04 | INSR; AKT1; PIK3R1; PIK3CG; IGF1R |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.890E-04 | 6.863E-04 | AKT1; MAPK1; PIK3R1; HIF1A; PIK3CG |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 2.530E-02 | 3.923E-02 | STAT6; NFKB1; TLR2 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 4.203E-04 | 9.569E-04 | SRC; ABL1; MAPK1; MAPK14; NFKB1 |
hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 4.086E-03 | 7.410E-03 | CAMK2B; GRIA2; MAOA; GRIA4 |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 2.740E-03 | 5.143E-03 | GRIA2; MAPK1; GRM1; IGF1R |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.792E-02 | 2.841E-02 | MAPK1; MAPK14; NFKB1 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.963E-02 | 3.089E-02 | AKR1B10; AKR1B1; GLA |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.629E-02 | 2.622E-02 | VCP; NFKB1; TLR2 |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 1.710E-02 | 2.730E-02 | MGAM; GAA; PYGL |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 1.502E-03 | 2.977E-03 | GRIA2; BCL2; MAPK14; TP53 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.100E-04 | 2.675E-04 | GRM3; GRIA2; GRM2; MAOA; NFKB1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 9.954E-05 | 2.477E-04 | PKM; INSR; MAPK1; PIK3R1; PIK3CG |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.073E-05 | 1.228E-04 | MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.004E-02 | 1.666E-02 | TK1; CYP3A4; XDH |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 9.371E-04 | 1.947E-03 | MGAM; AKT1; PIK3R1; PIK3CG |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 5.413E-04 | 1.194E-03 | INSR; MAPK1; PIK3R1; PIK3CG |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 8.603E-04 | 1.823E-03 | ABCC1; ABCB1; CFTR; ABCG2 |
hsa05033 | Nicotine addiction_Homo sapiens_hsa05033 | 6.820E-03 | 1.187E-02 | GRIA2; GABRR1; GRIA4 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 2.803E-02 | 4.315E-02 | MAPK1; EGFR |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 9.543E-06 | 3.094E-05 | MGAM; AKR1B10; GAA; AKR1B1; GLA |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.727E-03 | 5.143E-03 | MAPK1; PPARG; TP53 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 4.681E-03 | 8.418E-03 | MAOA; AOX1; TYR |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 3.958E-03 | 7.239E-03 | POLB; PARP1; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.072E-02 | 3.236E-02 | CA2; CA4 |
hsa00760 | Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | 2.727E-03 | 5.143E-03 | PNP; AOX1; CD38 |
hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 7.889E-03 | 1.351E-02 | ALPL; ALPI |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.183E-04 | 1.927E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
C00-D49: Neoplasms | Refractory cutaneous T-cell lymphoma | NA | PNP |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1; PTAFR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; DNMT1; DNMT1; AURKB; TERT; TP53; TP53; TK1 |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1 |
NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2; ADORA3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; GRM5 |
G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | GRM2 |
N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; PTAFR; FLT3; EGFR; MAPK14; BCL2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; PIK3CG; FLT3; ABL1; EGFR; TERT; TLR2; BCL2; ESR1; TK1 |
NA: NA | Primary insomnia | NA | HTR2C |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PTAFR; PARP1 |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; MGAM; PIK3CG; KDR |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; PTGS1; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; ALOX5; SYK |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | PTAFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
NA: NA | Joint and muscular pain | NA | PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; GRIK1; GRIK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; PPARG; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; TBXAS1; MGAM; PTPN1; PTPN1; PIK3CG; PIK3CG; INSR; PTGS2; NFKB1; PPARG; PPARG; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; MMP13; GRIK1; GRM1; PTAFR; OPRD1; INSR; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; CDK1; ADRA2C; ADRA2A; HTR2C; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; ABCB1; SYK; PTAFR; PIK3CG; FLT3; CA9; ABL1; EGFR; MMP2; MMP14; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TLR2; TP53; KDR; KDR; KDR; TOP2A; TK1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; DRD3; DRD4 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1 |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3; EGFR |
NA: NA | Colour dead tissues | NA | PTPN1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; HTR2C; HTR2C; PPARG; PPARD; PPARD |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; ESRRA; INSR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; ABCB1; AXL; EGFR; EGFR; DNMT1; PTGS2; IGF1R; IGF1R; KDR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; PTAFR; PIK3CG; MMP12; PTGS1; PTGS2; MAPK14 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
NA: NA | Inflammatory diseases | NA | MAPK14 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
NA: NA | Enthesopathy | NA | PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | DNMT1; DNMT1; TLR2; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; PIK3CG; PIK3CG; INSR; CA9; EGFR; HIF1A; BCL2 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR; MMP2 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1; PPARG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; GRM1; HTR2C; GRM3; GRM2; DRD3; DRD4 |
A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | PTAFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3; PARP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ABL1; BCL2; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; PTK2; TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
NA: NA | Dyslipidemia | NA | PPARD |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; SYK; OPRD1; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; MAPK14; TYR; PNP; MMP1 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2; MAPK14 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; GRIK1; GRM1; PTGS1; PTGS2; PTGS2; ADRA2B; GRM5 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG |
C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1; EGFR; EGFR; MMP2; TERT; PARP1; KDR; KDR; KDR; KDR |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; CD38; TP53 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1; PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; PPARG; DRD3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | GRM2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; EGFR; MMP2; PTGS2; TERT; TLR2; KDR; TK1 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; GRIA4; ACHE; GRIA2 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
NA: NA | HIV infections | NA | AHR |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1; PTAFR; PTGS1; PTGS2; MAPK14; PPARG |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; EGFR; CYP19A1 |
C00-D49: Neoplasms | B-cell acute lymphoblastic leukemia | NA | PNP |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; PIK3CG; CYP2C9 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR; TLR2; PNP; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Autism | F84.0 | GRM5 |
H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | PTAFR |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
NA: NA | Edema | NA | CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; MGAM; PTPN1; INSR; GSK3B; HTR2C; PPARG |
A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C; HTR2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; PIK3CG; PTGS2; PTGS2; MAPK14; MMP1 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; ALOX5; MMP12; PPARD |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | SLC6A1 |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; VCP; SRC; IGF1R; TERT; CD38; BCL2 |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Moderate-to-severe plaque psoriasis | L40 | PNP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR2C; GRM5; GRM2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PPARG; PNP |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR; DNMT1; SRC |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; ABL1; EGFR; EGFR; KDR; APP |
NA: NA | GERD | NA | GRM5 |
NA: NA | Geographic retinal atrophy | NA | APP |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADORA3; ADRA2C; CA1; CA1 |
NA: NA | GIST | NA | FLT3 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B; PTAFR |
N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1 |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM; GAA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TERT; TP53; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; PLA2G1B; ESRRA; ALOX5; ALOX5; SYK; SYK; PTAFR; MMP12; PTGS2; ADRA2C |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; SRC; TERT; ESR1; TK1 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; PIK3CG; INSR; FLT3; FLT3; CA9; EGFR; EGFR; EGFR; IGF1R; TERT; CYP19A1; CDK1; BCL2; ESR1; ESR1; KDR; KDR; KDR |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1; PTAFR |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; EGFR; EGFR; PTGS1; IGF1R; MMP9; TP53; KDR |
H00-H59: Diseases of the eye and adnexa | Conjunctivitis | H10 | PTAFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | MYLK; CA2; CA1 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | PTAFR; MMP9 |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB; INSR; PPARD; ESR1 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRIK1; GRM1; ADRA2C; NPSR1; HTR2C; GRM5; GRM4; ESR1; APP |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12; MAPK14 |
G00-G99: Diseases of the nervous system G00-G99 | Chronic neuropathic pain | G64, G90.0, K21, R52, G89 | GRM5; GRM5 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR; BCL2 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1; SRC |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; DRD3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Fragile X syndrome | F02.3, G20, Q99.2 | GRM5 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; KDR; KDR |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; GRM1; INSR; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; PPARG; PPARG; GRM5; GRM3; GRM2; APP |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK; PTAFR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | PTAFR |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; GRM5; PPARD; GRM2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; GRIK1; OPRD1; ADRA2C; ADRA2B; HTR2C |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; OPRD1; ACHE; HTR2C; GRM5; GRM3; GRM4; CYP3A4; GRM2 |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
NA: NA | Angioedema | NA | PIK3CG |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
NA: NA | Menopausal disorder | NA | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | EGFR; TERT; PARP1; TLR2; TYR; KDR; KDR |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; ADORA3; PARP1 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; MCL1; CSNK2A1; ABCB1; SYK; PIK3CG; FLT3; FLT3; CA9; ABL1; EGFR; MMP2; ACHE; DNMT1; PTGS2; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MAPK14; MMP9; NFKB1; PIM1; PARP1; CD38; TLR2; BCL2; BCL2; TP53; ESR1; ESR1; CA1; KDR; TK1; APP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; DRD3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; OPRD1; HTR2C; HTR2C; GRM5; GRM5; GRM3; GRM2; GRM2 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
NA: NA | Male hypogonadism | NA | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |